Arq. Bras. Cardiol. 2023; 120(12): e20230167
New Cardiovascular Biomarkers in Breast Cancer Patients Undergoing Doxorubicin-Based Chemotherapy
Rodrigo Mendonça Cardoso Pestana
, Júnea Paolucci Paiva Silvino, Angélica Navarro de Oliveira
, Cintia Esteves Soares, Adriano de Paula Sabino
, Ricardo Simões, Karina Braga Gomes
This Original Article is referred by the Short Editorial "Biomarkers in the Evaluation of Patients Undergoing Chemotherapy with Anthracyclines".
Introduction
Cardiovascular diseases (CVDs) and cancer are the leading causes of death worldwide. Continuous improvements in strategies for prevention and anti-cancer treatments in patients with breast cancer significantly reduced the death from cancer-related causes; however, there was an increased risk of death from CVD in this group of patients. The reasons for this synergism between cancer and CVD are the common risk factors (including diabetes mellitus, hypertension, hypercholesterolemia, and obesity), as well as pathophysiological mechanisms underlying CVD that are associated with an increased risk of cancers. ,
Anthracycline-based regimens, like doxorubicin (DOXO), are some of the most effective treatments against breast cancer and are responsible for improved disease-free survival and overall survival in this group. Nevertheless, anthracyclines can result in severe short and long-term toxicity, including cardiotoxicity and secondary hematological malignancy.
[…]
Keywords: Biomarkers; Breast Neoplasms; Cardiovascular Diseases; Doxorubicin
949
